Full Press Release Details
Tiziana Life Sciences plc
("Tiziana" or the "Company")
Tiziana Life Sciences to Participate
in a Fireside Chat at B. Riley Virtual Oncology Investor Conference:
on 21 January 2021 at 3 pm ET/8 pm GMT
NEW YORK and LONDON - 20 January
2021 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"),
a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced
its CEO and CSO, Dr. Kunwar Shailubhai, will participate in a fireside chat via a video link on Thursday 21 January 2021 at 3 pm
ET / 8 pm GMT to provide updates on the Company.
| Date: | Thursday 21 January 2021 |
| Time: | 3 pm U.S. Eastern / 8 pm GMT |
| Webcast: | https://b-riley-oncology-investor-conference.events.issuerdirect.com/signup |
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology
company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In
addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3
monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune
and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes
(T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is
accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced
inflammation, especially for treatment of COVID-19 patients.
For further enquiries:
United Kingdom Investors:
United States Investors: